Sara A. Hurvitz, MD, David Geffen School of Medicine

Treatment Advances in HR+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 19th 2021

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 19th 2021

Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.

The PRIME II Study in HR+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 19th 2021

Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.

The PENELOPE-B Study in HR+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 12th 2021

Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.

Updated Results of MonarchE in HR+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 12th 2021

Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.

Rationale for Ovarian Suppression in HR+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

March 5th 2021

During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.